Dupixent (dupilumab)

pCPA File Number: 21225

Negotiation Status:

Concluded with an LOI

Indication(s):

Atopic dermatitis

Sponsor/Manufacturer:

Sanofi Genzyme Canada

CDA-AMC Project Number:

SR0636-000

pCPA Engagement Letter Issued:

2020-07-28

Negotiation Process Concluded:

2021-02-25